The Supreme Court's rejection of Martin Shkreli's appeal regarding the return of $64.6 million marks the end of a legal battle over his controversial price hike of the essential drug Daraprim.
Prosecutors successfully argued that Shkreli orchestrated an illegal scheme, raising the price of Daraprim from $13.50 to $750 overnight, reflecting rampant greed in the pharmaceutical industry.
The Federal Trade Commission accused Shkreli of creating a "web of anticompetitive restrictions" to eliminate competition, which US District Court Judge Denise Cote described as "egregious, deliberate, and dangerous."
Shkreli's actions came to symbolize greed within the pharmaceutical sector, culminating in a legal conclusion that his practices were harmful and obstructive to market competition.
Collection
[
|
...
]